TRCT
LXRX icon

Tower Research Capital (TRC)’s Lexicon Pharmaceuticals LXRX Stock Holding History

Tower Research Capital (TRC)’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-29,093
Closed -$33.5K – 5372
2025
Q4 		$33.5K Buy
29,093
+5,414
+23% +$7.44K ﹤0.01% 2724
2025
Q3 		$32K Buy
23,679
+10,989
+87% +$12.5K ﹤0.01% 2890
2025
Q2 		$12K Sell
12,690
-15,417
-55% -$9.99K ﹤0.01% 3898
2025
Q1 		$13K Buy
28,107
+15,952
+131% +$10.1K ﹤0.01% 3411
2024
Q4 		$8.98K Buy
12,155
+6,184
+104% +$7.45K ﹤0.01% 3947
2024
Q3 		$9.37K Sell
5,971
-10,981
-65% -$19.6K ﹤0.01% 3873
2024
Q2 		$28.5K Sell
16,952
-1,085
-6% -$1.95K ﹤0.01% 3524
2024
Q1 		$43.3K Buy
18,037
+2,116
+13% +$4.55K ﹤0.01% 2384
2023
Q4 		$24.4K Sell
15,921
-1,009
-6% -$1.2K ﹤0.01% 3534
2023
Q3 		$18.5K Sell
16,930
-27,648
-62% -$48.5K ﹤0.01% 3448
2023
Q2 		$102K Buy
44,578
+38,967
+694% +$103K ﹤0.01% 2010
2023
Q1 		$13K Sell
5,611
-713
-11% -$1.63K ﹤0.01% 3982
2022
Q4 		$12K Sell
6,324
-13,065
-67% -$27.8K ﹤0.01% 3724
2022
Q3 		$46K Buy
19,389
+13,232
+215% +$36.6K ﹤0.01% 3234
2022
Q2 		$11K Sell
6,157
-10,108
-62% -$19.3K ﹤0.01% 4378
2022
Q1 		$34K Buy
16,265
+8,584
+112% +$23.8K ﹤0.01% 3036
2021
Q4 		$30K Sell
7,681
-7,319
-49% -$35.5K ﹤0.01% 3224
2021
Q3 		$73K Buy
15,000
+11,143
+289% +$45.7K ﹤0.01% 2666
2021
Q2 		$18K Sell
3,857
-2,267
-37% -$10.9K ﹤0.01% 3997
2021
Q1 		$36K Sell
6,124
-989
-14% -$6.85K ﹤0.01% 3400
2020
Q4 		$24K Sell
7,113
-39,594
-85% -$75.5K ﹤0.01% 3746
2020
Q3 		$67K Buy
46,707
+26,929
+136% +$47.9K ﹤0.01% 3411
2020
Q2 		$40K Buy
+19,778
New +$38.8K ﹤0.01% 3229
2020
Q1 		– Sell
-4,329
Closed -$18K – 3533
2019
Q4 		$18K Buy
+4,329
New +$16.7K ﹤0.01% 1995
2019
Q3 		– Sell
-93
Closed -$1K – 4343
2019
Q2 		$1K Sell
93
-1,118
-92% -$6.69K ﹤0.01% 3454
2019
Q1 		$7K Sell
1,211
-683
-36% -$4.15K ﹤0.01% 2875
2018
Q4 		$13K Buy
1,894
+1,273
+205% +$10.3K ﹤0.01% 2261
2018
Q3 		$7K Sell
621
-6,822
-92% -$78.2K ﹤0.01% 2965
2018
Q2 		$89K Buy
7,443
+6,959
+1,438% +$71.2K 0.01% 1505
2018
Q1 		$4K Buy
484
+293
+153% +$2.71K ﹤0.01% 2795
2017
Q4 		$2K Sell
191
-3,152
-94% -$32.8K ﹤0.01% 3221
2017
Q3 		$41K Buy
+3,343
New +$49.4K ﹤0.01% 2150
2017
Q1 		– Sell
-1,740
Closed -$24K – 3549
2016
Q4 		$24K Buy
+1,740
New +$27.9K ﹤0.01% 1976
2016
Q1 		– Sell
-720
Closed -$10K – 4592
2015
Q4 		$10K Sell
720
-8,874
-92% -$109K ﹤0.01% 2125
2015
Q3 		$103K Buy
9,594
+9,383
+4,447% +$102K 0.01% 547
2015
Q2 		$2K Sell
211
-1,375
-87% -$10.1K ﹤0.01% 3743
2015
Q1 		$10K Buy
+1,586
New +$10.8K ﹤0.01% 2794
2014
Q4 		– Sell
-10,099
Closed -$100K – 4390
2014
Q3 		$100K Buy
+10,099
New +$108K 0.01% 942
2014
Q2 		– Sell
-14
Closed – – 4371
2014
Q1 		$0 Sell
14
-14,868
-100% -$190K ﹤0.01% 4714
2013
Q4 		$187K Buy
14,882
+14,718
+8,974% +$234K 0.03% 555
2013
Q3 		$3K Sell
164
-264
-62% -$4.43K ﹤0.01% 3954
2013
Q2 		$6K Buy
+428
New +$6.5K ﹤0.01% 2810

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Tower Research Capital (TRC)'s LXRX Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2026, closing a stake of 29,093 shares — an estimated $33.5K sold.

Tower Research Capital (TRC) first reported a position in LXRX in Q2 2013 and held it in 42 quarters. The position peaked at $187K in Q4 2013. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining Lexicon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 29,093 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $33.5K.
  • Tower Research Capital (TRC) first reported a position in Lexicon Pharmaceuticals in Q2 2013 and held it in 42 quarters.
  • Tower Research Capital (TRC)'s Lexicon Pharmaceuticals position peaked at $187K in Q4 2013.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.